Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.
- FIG stock is climbing. See the chart and price action here.
A scan was run, using the Benzinga Pro screener, to identify the most heavily shorted stocks in the market.
The image below shows the top 10 most heavily shorted stocks (market caps above $2 billion and average 14-day volumes above 5 million) based on data from Benzinga Pro as of July 13, 2026:
Top 10 Most Shorted Stocks
Lucid Group Inc. (NASDAQ:LCID) tops the list, with nearly half its float sold short, a stark referendum on EV execution that could reverse violently if deliveries, funding or cost controls surprise to the upside.
Figma Inc. (NYSE:FIG) isn’t far behind, as shorts lean hard into the trade on fears that growth has already peaked.
CleanSpark Inc. (NASDAQ:CLSK) sits firmly in the crosshairs, where crypto‑linked volatility and an evolving energy story give bears plenty of narrative ammunition—and bulls plenty of potential catalysts.
SoundHound AI Inc. (NASDAQ:SOUN) adds an AI‑flavored twist, with more than 40% of float shorted in a name where headlines and hype can move faster than the underlying fundamentals.
Fluence Energy Inc. (NASDAQ:FLNC) and UiPath Inc. (NYSE:PATH) extend the theme into grid‑scale storage and automation software, both carrying high‑30s short‑interest readings as traders question how quickly these business models can scale profitably.
Under Armour Inc. (NYSE:UAA) brings consumer‑discretionary risk into the mix, with shorts betting that brand heat and margin recovery will remain elusive.
High short interest in drone maker Ondas Holdings Inc. (NASDAQ:ONDS) likely reflects skepticism toward niche industrial and connectivity plays.
Tempus AI Inc. (NASDAQ:TEM) shows how even a data‑driven healthcare analytics name can become a crowded downside trade when investors question the durability of its growth, reimbursement tailwinds and hospital spending on AI‑powered decision support.
ImmunityBio Inc. (NASDAQ:IBRX) rounds out the group, where elevated short interest highlights how binary biotech sentiment can be around trial timelines and regulatory decisions.
With short‑interest readings clustered in the mid‑30% to mid‑40% range, this entire basket is highly sensitive to any shift in risk appetite or a string of better‑than‑feared company updates.
A more supportive macro backdrop, lower‑for‑longer rate expectations or one well‑timed positive headline per name could turn today’s consensus bearish trades into tomorrow’s forced‑buying stampedes.
Photo: NESPIX / Shutterstock
Login to comment